Cancer Research Annual Meeting 2010  2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 22, 56-61, January 1, 1962]
© 1962 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacquez, J. A.
Right arrow Articles by Sherman, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacquez, J. A.
Right arrow Articles by Sherman, J. H.

Enzymatic Degradation of Azaserine*

John A. Jacquez and James H. Sherman

( Division of Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research, and the Sloan-Kettering Division, Cornell University Graduate School of Medical Sciences, New York, N.Y.)

Mouse liver contains an enzyme which rapidly decomposes certain O-esters of L-serine to give pyruvate and ammonia. Kidney, spleen, intestine, and muscle have much lower enzyme activities. The enzyme has a broad pH optimum of around 7.2. It is inhibited by fluoride but not by versene, dithizone, or cyanide. The Km for azaserine is 2.3–2.4 · 10-3 M at pH 7.3–7.4. The best substrates for the enzyme are O-esters of serine in which the terminal groups on the acid moiety are relatively nonionized. The reaction mechanism is probably an {alpha} elimination which gives the acid, pyruvate, and ammonia as end-products.

* This work was supported by grants T36 and T37 from the American Cancer Society and by CCNSC contract #SA-43-ph-2445 and Training grant #5015, National Cancer Institute, Public Health Service.

Received 7/20/61.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1962 by the American Association for Cancer Research.